Advertisement Covers CROI 2017


Being Underweight or Obese Tied to Serious Non-AIDS Illnesses in D:A:D Study

February 28, 2017

Low body mass index (BMI) -- even below 23 kg/m2 -- predicted serious non-AIDS events and all-cause mortality in a 41,149-person D:A:D study analysis. Obesity, but not being overweight, also predicted mortality and serious non-AIDS events, including cardiovascular disease and cancers.

Overweight and obesity prevalence is rising in HIV-positive people taking antiretroviral therapy (ART). Research in the general population links being overweight and obesity to cardiovascular disease, diabetes, certain cancers and mortality. Low BMI also carries risks. D:A:D: study investigators scrutinized their cohort to gauge the impact of BMI on serious non-AIDS events and death in adults taking ART.

D:A:D is a multi-cohort prospective study in Europe, the United States and Australia. The analysis included D:A:D members with at least one BMI measured when they started ART or afterwards and at least one year of follow-up. The researchers excluded people who already had cardiovascular disease, diabetes or cancer. Follow-up continued until a non-AIDS event developed or until death, six months after the last follow-up visit or February 2014. Centrally adjudicated events were cardiovascular disease (myocardial infarction, stroke or invasive cardiovascular procedures), diabetes, non-AIDS cancers, BMI-related non-AIDS cancers (esophageal, pancreatic, colon, rectal, breast, endometrial, kidney, thyroid, gallbladder) and all-cause mortality.

Related: Classic Risk Factors Drive Heart Attack Rates More Than HIV Variables

The investigators considered BMI as a time-updated variable lagged by one or two years (meaning events counted only if they occurred one or two years after the BMI measurement). They divided participants into six BMI groups: under 18.5 kg/m2, 18.5 to 23 kg/m2, 23 to 25 kg/m2, 25 to 27.5 kg/m2, 27.5 to 30 kg/m2 and more than 30 kg/m2. In the general population a BMI below 18.5 kg/m2 is considered underweight, 18.5 to 25 kg/m2 normal, 25 to 30 kg/m2 overweight and above 30 kg/m2 obese. The six BMI ranges in the D:A:D analysis included (in order) 1,929; 17,640; 9,283; 6,998; 2,910 and 2,389 people. Baseline age averaged 40.4 years, 73.5% of participants were men and median baseline CD4 count measured 410 cells/mm3.

Through 295,147 person-years of follow-up, event incidence per 1000 person-years measured 4.8 for cardiovascular disease, 4.2 for diabetes, 3.9 for non-AIDS cancers, 0.6 for BMI-related non-AIDS cancers, 11.2 for all-cause mortality in men and 7.8 for all-cause mortality in women.

Poisson regression models adjusted for key confounders consistently linked BMI below 18.5 or between 18.5 and 23 kg/m2 to higher relative risk of all-cause mortality and of all serious non-AIDS events except diabetes when compared with a BMI of 23 to 25 kg/m2 (the reference value throughout). Regression analysis tied BMI above 30 kg/m2 (but not between 25 and 30 kg/m2) to higher relative risk of cardiovascular disease, BMI-related non-AIDS cancers and all-cause mortality. Diabetes had a linear relationship with BMI, climbing from an incidence rate ratio (IRR) below 1.0 in people below 23 kg/m2 and rising through BMI brackets above 25 kg/m2 to an IRR of about 3.5 in obese people. Results were similar for all outcomes when the researchers lagged time-updated BMI by two years instead of one year.

Except with diabetes, the researchers conclude, BMI had a statistically significant J-shaped relationship to risk of serious non-AIDS events and mortality: In other words, compared with a BMI of 23 to 25 kg/m2, a BMI below 23 kg/m2 or above 30 kg/m2 was associated with higher risk of non-AIDS events or death. Notably, a BMI of 20 to 23 kg/m2 is typically considered normal. The D:A:D: team cautions that the findings are limited by the lower number of cohort members in the upper and lower extremes of BMI. They also note that BMI has limits as a marker of body weight or fat.

Mark Mascolini writes about HIV infection.

Related Stories

Classic Risk Factors Drive Heart Attack Rates More Than HIV Variables
HIV Vaccine Plus Latency Reactivator Induces Sustained HIV Remission in Proof-of-Concept Study
Two-Drug Regimen Shines in HIV Treatment Switch Study

This article was provided by TheBodyPRO. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.